CoChat

Addition of interferon‐α to the p53‐SLP® vaccine results in increased production of interferon‐γ in vaccinated colorectal cancer patients: A phase I/II clinical trial

Open access
Zeestraten, Eliane C.M., Speetjens, Frank M., Welters, Marij J.P., Saadatmand, Sepideh, Stynenbosch, Linda F.M., Jongen, Rogier, Kapiteijn, Ellen, Gelderblom, Hans, Nijman, Hans W., Valentijn, A. Rob P.M., Oostendorp, Jaap, Fathers, Lorraine M., Drijfhout, Jan W., van de Velde, Cornelis J.H., Kuppen, Peter J.K., van der Burg, Sjoerd H., Melief, Cornelis J.M. · 2013 · International Journal of Cancer
Cited by 61

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

We previously established safety and immunogenicity of a p53 synthetic long peptides (p53‐SLP®) vaccine. In the current trial, we investigated whether combination of interferon‐alpha (IFN‐α) with p53‐SLP® is both safe and able to improve the induced p53‐specific IFN‐γ response. Eleven colorectal cancer patients successfully treated for metastatic disease were enrolled in this study. Of these, nine patients completed follow‐up after two injections with p53‐SLP® together with IFN‐α. Safety and p53‐specific immune responses were determined before and after vaccination. Furthermore, cryopreserved PBMCs were compared head‐to‐head to cryopreserved PBMCs obtained in our previous trial with p53‐SLP® only. Toxicity of p53‐SLP® vaccination in combination with IFN‐α was limited to Grade 1 or 2, with predominantly small ongoing swellings at the vaccination site. All patients harbored p53‐specific T cells after vaccination and most patients showed p53‐specific antibodies. Compared to the previous trial, addition of IFN‐α significantly improved the frequency of p53‐specific T cells in IFN‐γ ELISPOT. Moreover, in this trial, p53‐specific T cells were detectable in blood samples of all patients in a direct ex vivo multiparameter flowcytometric assay, opposed to only 2 of 10 patients vaccinated with p53‐SLP® only. Finally, patients in this trial displayed a broader p53‐specific immunoglobulin‐G response, indicating an overall better p53‐specific T‐helper response. Our study shows that p53‐SLP® vaccination combined with IFN‐α injection is safe and capable of inducing p53‐specific immunity. When compared to a similar trial with p53‐SLP® vaccination alone the combination was found to induce significantly more IFN‐γ producing p53‐specific T cells.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ijc.27819

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 61

Metadata

Authors
Zeestraten, E. C. M., Speetjens, F. M., Welters, M. J. P., Saadatmand, S., Stynenbosch, L. F. M., Jongen, R., Kapiteijn, E., Gelderblom, H., Nijman, H. W., Valentijn, A. R. P. M., Oostendorp, J., Fathers, L. M., Drijfhout, J. W., van de Velde, C. J. H., Kuppen, P. J. K., van der Burg, S. H., & Melief, C. J. M.
Venue
International Journal of Cancer
Publisher
Wiley
Published
2012-11-21
Volume
132
Issue
7
Pages
1581-1591
ISSN
  • 0020-7136 (ISSN-L)
  • 1097-0215
OpenAlex
W2120270602
Cited by
61
References
2
FWCI
3.70
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Addition of interferon‐α to the p53‐SLP® vaccine results in increased production of interferon‐γ in vaccinated colorectal cancer patients: A phase I/II clinical trial. https://app.cochat.ai/papers/10.1002/ijc.27819
The paper
Zeestraten, E. C. M., Speetjens, F. M., Welters, M. J. P., Saadatmand, S., Stynenbosch, L. F. M., Jongen, R., Kapiteijn, E., Gelderblom, H., Nijman, H. W., Valentijn, A. R. P. M., Oostendorp, J., Fathers, L. M., Drijfhout, J. W., van de Velde, C. J. H., Kuppen, P. J. K., van der Burg, S. H., & Melief, C. J. M. (2013). Addition of interferon‐α to the p53‐SLP® vaccine results in increased production of interferon‐γ in vaccinated colorectal cancer patients: A phase I/II clinical trial. International Journal of Cancer. https://doi.org/10.1002/ijc.27819

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.